Actinium Pharmaceuticals
ATNM
40 hedge funds and large institutions have $9.99M invested in Actinium Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 15 closing their positions.
2,941% more call options, than puts
Call options by funds: $16.9M | Put options by funds: $555K
5.1% less ownership
Funds ownership: 14.75% → 9.65% (-5.1%)
17% less funds holding
Funds holding: 48 → 40 (-8)
36% less capital invested
Capital invested by funds: $15.6M → $9.99M (-$5.64M)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$331K |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$295K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$132K |
| 4 |
BC
BIT Capital
Berlin,
Germany
|
+$120K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$117K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$690K |
| 3 |
D.E. Shaw & Co
New York
|
-$501K |
| 4 |
Millennium Management
New York
|
-$429K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$395K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| – | -$2.34K | -276 | -76% |
|
|
TC
52
Truvestments Capital
Sarasota,
Florida
| – | -$1.27K | -150 | -71% |
|
ATNM Hedge Fund Activity: Q1 2021 in Review
40 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2021, worth a combined $9.99M — down 36% from $15.6M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ATNM and 7 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 7 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $331K. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $2.3M sold.
- 40 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2021, down from 48 in Q4 2020.
- Funds reported $9.99M of Actinium Pharmaceuticals stock for Q1 2021, down 36% quarter-over-quarter.
- 7 funds opened new Actinium Pharmaceuticals positions in Q1 2021 and 15 closed out, a net change of -8 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2021 was GSA Capital Partners, an estimated $331K added.
- The largest Actinium Pharmaceuticals seller in Q1 2021 was Rubric Capital Management (New York), an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2021.